Diality is a medical device company that aims to improve lives impacted by kidney disease through the development of the next generation of hemodialysis machines for at-clinic or at-home usage. A hemodialysis machine continuously extracts blood from a patient, runs it through a dialyzer--which acts as an artificial kidney to filter out waste and excess fluids--and reintroduces the filtered blood into the patient's system. This treatment process occurs three times per week for three to four hours per session depending on the patient's support needs. A common issue with treatment currently is knowing the correct Blood Volume Removal Rate (BVRR) for each patient. If the BVRR is too low, the treatment becomes inefficient and takes longer than required, but if it is too high, the patient's blood pressure could drop significantly putting the patient at risk of complications such as dizziness or loss of consciousness. Poor reactions such as these would require the treatment to be stopped immediately, necessitating another full day of treatment to make up for the lost time. Currently, there is no device on Diality’s machines that gauges the patient’s ratio of red blood cells to total volume, or Hematocrit (HCT), in real time. By having a direct input of the patient’s hematocrit value, caretakers or clinical professionals would be able to monitor the BVRR and adjust the treatment as necessary to improve the patient's treatment experience and overall outcomes.
This project directly benefits physicians, clinics, and most importantly patients by streamlining their treatment and mitigating the test-and-adjust period most patients experience when they first receive dialysis treatment. This sensor will help ensure minimal disruption to the patients' treatment and improve their quality of life
